SCHEMBL982690

SCHEMBL982690

O/N=C/c1cccnc1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL982692 1.00
SCHEMBL2009628 1.00
SCHEMBL29870038 1.00
SCHEMBL29603790 1.00
Hydrochloric Acid SCHEMBL27310875 0.98 ALDH1A1 (0.67)
Propane SCHEMBL20456167 0.91 ALDH1A1 (0.58)
SCHEMBL28073535 0.82 ALDH1A1 (1.00)
SCHEMBL27361416 0.80 CYP2A6 (0.51)
SCHEMBL13074016 0.79 CYP2A6 (0.58)
SCHEMBL3644281 0.79 CYP2A6 (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11424006-B2 Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide PSOMAGEN, INC. (US) 2022-08-23 US claimed
US-20210128498-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE MACROGEN INC. (KR) 2021-05-06 US claimed
EP-3668494-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE Psomagen, Inc. (US) 2020-06-24 EP claimed
CN-111163761-A Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide 普梭梅根公司 2020-05-15 CN claimed
WO-2019036507-A1 TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE uBiome, Inc. (US) 2019-02-21 WO claimed
US-20190050525-A1 RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES PSOMAGEN, INC. 2019-02-14 US claimed
EP-1527165-A4 A RHODOCOCCUS GENE ENCODING ALDOXIME DEHYDRATASE DU PONT (US) 2006-06-07 EP claimed
EP-1527165-A2 A RHODOCOCCUS GENE ENCODING ALDOXIME DEHYDRATASE E.I. du Pont de Nemours and Company (US) 2005-05-04 EP claimed
US-20030215929-A1 Rhodococcus gene encoding aldoxime dehydratase E. I. DU PONT DE NEMOURS AND COMPANY 2003-11-20 US claimed
WO-2003078581-A2 A RHODOCOCCUS GENE ENCODING ALDOXIME DEHYDRATASE E.I. DU PONT DE NEMOURS AND COMPANY (US) 2003-09-25 WO claimed
US-12275739-B2 Inhibitors of menin-MLL interaction BIOMEA FUSION, INC. (US) 2025-04-15 US disclosed
US-20240140953-A1 INHIBITORS OF MENIN-MLL INTERACTION BIOMEA FUSION, INC. 2024-05-02 US disclosed
US-20240122179-A1 AUXINIC HERBICIDES AND METHODS OF USE THEREOF CORTEVA AGRISCIENCE LLC (US) 2024-04-18 US disclosed
CN-117813004-A Auxin herbicide and application method thereof 科迪华农业科技有限责任公司 2024-04-02 CN disclosed
CN-114380825-B Substituted pyrazole condensed ring derivative and preparation method and application thereof 北京志健金瑞生物医药科技有限公司 2024-02-13 CN disclosed
US-5780490-A A O-(2,4-OXA(OR THIA)ZOLIDINYL)PHENYLOXY(OR THIO OR AMINO) ALKYLOXIME; ALDOSE REDUCTASE INHIBITORS; ANTIDIABETIC AND -HYPOGLYCEMIC AGENTS; LIVER, SKIN AND UROGENITAL DISORDERS SANKYO COMPANY, LIMITED (JP) 1998-07-14 US disclosed
US-5703096-A ANTIDIABETIC AGENTS; ALDOSE REDUCTASE INHIBITOR SANKYO COMPANY, LIMITED (JP) 1997-12-30 US disclosed
EP-0708098-A1 Oxime derivatives, their preparation and their therapeutic use SANKYO COMPANY LIMITED (JP) 1996-04-24 EP disclosed
US-5180832-A Chemical intermediate for thromboxane A2 inhibitor JANSSEN PHARMACEUTICA N.V. (BE) 1993-01-19 US disclosed
US-4746671-A THROMBOXANE SYNTHETASE INHIBITION JANSSEN PHARMACEUTICA N.V. (BE) 1988-05-24 US disclosed